Calton & Associates’s Imunon IMNN Stock Holding History

Calton & Associates’s Portfolio IMNN Stock Details IMNN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-82	Closed	-$60K	–	359
2020 Q2	$60K	Buy	+82	New	+$35.6K	0.01%	324

Other funds holding IMNN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Calton & Associates's IMNN Position: Q3 2020 in Review

Calton & Associates sold out of Imunon (IMNN) in Q3 2020, closing a stake of 82 shares — an estimated $60K sold.

Calton & Associates first reported a position in IMNN in Q2 2020 and held it in 1 quarter. The position peaked at $60K in Q2 2020. 34 funds tracked by Wall St. Rank hold IMNN as of Q3 2020.

Calton & Associates reported no remaining Imunon position as of Q3 2020 after selling out during the quarter.
Calton & Associates sold 82 Imunon shares in Q3 2020, an estimated $60K.
Calton & Associates first reported a position in Imunon in Q2 2020 and held it in 1 quarter.
Calton & Associates's Imunon position peaked at $60K in Q2 2020.
34 funds tracked by Wall St. Rank held Imunon as of Q3 2020.

Based on Calton & Associates's 13F filing for Q3 2020, filed 30 Oct 2020.